The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•1 May 2026•

1 min read

Arrowhead Pharmaceuticals Gains Australian TGA Approval for REDEMPLO in FCS Treatment

Key Facts

1The Australian Therapeutic Goods Administration (TGA) approved REDEMPLO (plozasiran) as an adjunct to diet for patients with familial chylomicronemia syndrome (FCS).

Arrowhead Pharmaceuticals has announced that the Australian Therapeutic Goods Administration (TGA) has approved its siRNA medicine, REDEMPLO (plozasiran). The drug is indicated as an adjunct to diet for adult patients suffering from familial chylomicronemia syndrome (FCS). This approval specifically addresses patients who have shown an inadequate response to standard existing therapies. By securing this regulatory milestone, Arrowhead expands the global reach of plozasiran for a rare disease characterized by dangerously high triglyceride levels. The approval marks a significant step forward for the company’s clinical portfolio in the biotechnology sector. This development is expected to strengthen Arrowhead's position in the specialized market for genetic lipid disorders.

Sources: